前列腺癌血清PSA、PAP测定与全身骨显像联合应用价值

前列腺癌血清ＰＳＡ、ＰＡＰ测定与全身骨显像联合应用价值邓守真蒯大禹方祖军宋建达何婉婷张学平程伟林祥通刘永昌笔者对１９９２年４月～１９９６年１０月经病理证实的１００例前列腺癌患者血清前列腺特异抗原（ＰＳＡ）、前列腺酸性磷酸酶（ＰＡＰ）测定及全身骨显像的...     

NSCLC患者血清肿瘤标志物水平与肿瘤骨转移之间关系的研究

目的:探讨非小细胞肺癌患者治疗前血清肿瘤标志物水平与肿瘤骨转移之间的相关性。材料和方法:受检患者58名治疗前均行血清Cy21-1、SCC、NSE、CEA和CA15-3测定和SPECT全身骨显像。结果:血清Cy21-1和CA15-3水平与全身骨显像结果相关。(P<0.05),血清SCC,NSE及CEA水平则无相关(P>0.05)。结论:血清中Cy21-1和CA15-3升高水平与肿瘤骨转移之间存在正相关关系,尤以Cy21-1为著。     

冒癌表达胃泌素受体的特征

目的 研究胃癌表达胃泌素受体(gastrin receptor,GR)的特征及意义。 方法 应用受体的放射配基结合分析法测定34例胃癌标本GR含量及其亲和力,并比较胃癌表达的GR与其部位、分期、分级、胃癌细胞DNA含量、邻近正常胃粘膜的GR及患者生存期的关系。 结果 34例胃癌组织中,16例(47.1％)胃癌GR阳性,其中14例(41.2％)表达高亲和力GR,2例表达低亲和力GR;在高亲和力GR中,9例表达高含量GR(平均含量39.5±14.4 fmol/mg蛋白),5例表达低含量GR(平均含量6.0±2.8 fmol/mg蛋白)。胃体癌(77.8％)和贲门癌(50％)较胃窦癌(20.1％)更易于表达高亲和力GR。相同部位的胃癌及邻近正常粘膜表达GR是一致的,但胃癌表达的胃泌素受体含量(39.5±14.4 fmol/mg蛋白)高于粘膜(26.1±16.6 fmol/mg蛋白)。Ⅲ、Ⅳ期胃癌表达高亲和力GR的比例(13/24)明显高于Ⅰ、Ⅱ期胃癌(1/10)。胃癌表达的GR与癌细胞的分级无关。随访23～61月发现,对于Ⅲ、Ⅳ期胃癌患者,13例表达高亲和力GR的胃癌,有11例死亡;而11例低亲和力GR或GR阴性的胃癌,仅有4例死亡。 结论 GR在胃癌自分泌生长过程中也是一个重要的因素;GR有利于预测患者的预后及指导GR拮抗剂的应用。     

鼠坐骨神经再生早期轴浆流改变的实验研究

目的探索同位素示踪早期检测神经再生的可行性，并与神经电图－肌电图检测结果进行比较，为临床应用奠定基础。方法将鼠坐骨神经切断并作神经缝合，术后１、２、３、４周用微量注射器将１２５Ｉ－酪氨酸直接注射入大鼠坐骨神经干内，于注射后８、１２、１６小时取样以γ－计数器检测其放射性。测定再生神经１２５Ｉ－酪氨酸转运规律，并与神经电图－肌电图检测结果、光镜下再生髓鞘形态学变化相比较。结果术后２周轴浆流即可通过缝合口，早于神经电图－肌电图出现时间；与再生髓鞘出现时间相符。结论应用轴浆流同位素示踪法早期检测神经再生，较神经电图－肌电图具有明显的优越性。     

胃肠道恶性肿瘤术后~（99m）Tc－植酸钠腹腔显像

胃肠道恶性肿瘤术后~（９９ｍ）Ｔｃ－植酸钠腹腔显像邓守真，金少津，林祥通，余枫，乐竹琴，张锦明胃肠道恶性肿瘤原发病灶切除后．常因腹腔内游离癌细胞种植导致腹腔内复发．本研究采用放射性核素腹腔显像，依据放射性在腹腔内分布情况，观察手术后及接受早期腹腔内导?..     

应用同位素~(125)碘标记蝮蛇毒在小白鼠体内的示踪观察

本文采用Greenwood氏方法(略作修改)制得~(125)碘—蝮蛇毒,实验对象为20克体重的小白鼠,共24只,分成8组,将~(125)碘—蝮蛇毒0.1毫升注射于小白鼠后腿内侧皮下。注射后各组分别于0.5、1、4、8、16、42、48、72小时处死解剖,取肋间肌、胃、肠、心、肺、肾、脊髓、脑等组织各取等量测定其所含~(125)碘—蝮蛇毒量,并求得每组动物的均值。结果发现小白鼠体内以胃、肾含量最多,肺、肝、心、肠、肋间肌、脊髓等次之,脑含量最少。蝮蛇毒在局部吸收迅速,半     

组织多肽特异性抗原对胰腺癌患者的诊断价值

Objective To compare the diagnostic value of tissue polypeptide specific antigen (TPS) in serum, with the carbohydrate antigens (CA) 19-9, CA50, CA125 and CA242 in pancreatic carci-noma. Methods Serum TPS was measured with enzyme linked immunosorbent assay (ELISA). CA19-9 and CA125 were measured with chemiluminescent immunoassay. CAS0 and CA242 were measured with im-munoradiometric assay in 33 patients with pancreatitis, 34 patients with pathologically proven pancreatic car-cinoma, and 35 patients with non-pancreatic malignancies. Statistic analysis was carried out with SPSS 9.0 software. Results Patients with pancreatic carcinoma had relatively higher levels of TPS [(386.5± 315. 1) U/L] and CA19-9 [(10 820.9 ± 389.7) kU/L] when compared with patients with pancreatitis [(86. 2 ± 28.1) U/L and (61.5 ± 24.7) kU/L, respectively; F = 936. 42, P < 0. 001 ; F = 2217. 09, P < 0. 001], with a sensitivity and a specificity of 70.6% (48/68) and 57.4% (39/68), respectively, for TPS, and 82.4% (28/34) and 77.9% (53/68), respectively, for CA19-9. Diagnostic performance was further improved when TPS was assayed in combination with CA19-9, CA50, CA12.5 and CA242. Conclusion Serum TPS has an incremental value in complementing CA19-9 in the diagnosis of pancreatic carcinoma.     

甲状腺机能亢进症实验室检查的合理选择探讨

本文回顾1970年来我院确诊为甲状腺机能亢进(下称甲亢)病例235名,结合近年来对甲亢的实验诊断工作,探讨其临床应用价值,并试拟一些合理选择的方案.下表为所进行的各项检查及其结果:讨论一、BMR:其准确性易受多种因素影响,但如能认真做好准备,技术无误,对甲亢的诊断符合率可达80％以上。二、PBI:正常时80～90％来自T_4,可大致反映血清 T_4浓度.但无特异性,受外源性含碘物质及血中某些蛋白成份,特别是甲状腺素结合球蛋白(TBG)含量的影响很大,故临床符合率欠佳.     

组织多肽特异性抗原对胰腺癌患者的诊断价值

Objective To compare the diagnostic value of tissue polypeptide specific antigen (TPS) in serum, with the carbohydrate antigens (CA) 19-9, CA50, CA125 and CA242 in pancreatic carci-noma. Methods Serum TPS was measured with enzyme linked immunosorbent assay (ELISA). CA19-9 and CA125 were measured with chemiluminescent immunoassay. CAS0 and CA242 were measured with im-munoradiometric assay in 33 patients with pancreatitis, 34 patients with pathologically proven pancreatic car-cinoma, and 35 patients with non-pancreatic malignancies. Statistic analysis was carried out with SPSS 9.0 software. Results Patients with pancreatic carcinoma had relatively higher levels of TPS [(386.5± 315. 1) U/L] and CA19-9 [(10 820.9 ± 389.7) kU/L] when compared with patients with pancreatitis [(86. 2 ± 28.1) U/L and (61.5 ± 24.7) kU/L, respectively; F = 936. 42, P < 0. 001 ; F = 2217. 09, P < 0. 001], with a sensitivity and a specificity of 70.6% (48/68) and 57.4% (39/68), respectively, for TPS, and 82.4% (28/34) and 77.9% (53/68), respectively, for CA19-9. Diagnostic performance was further improved when TPS was assayed in combination with CA19-9, CA50, CA12.5 and CA242. Conclusion Serum TPS has an incremental value in complementing CA19-9 in the diagnosis of pancreatic carcinoma.